Updated Jul 16, 2026
RAGUSA ROBERT P is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $17.92M.
Robert P. Ragusa is the Chief Executive Officer and Director of GRAIL, Inc., a healthcare company specializing in early cancer detection technologies. He has been involved in the company through various SEC filings, indicating his active role in corporate governance.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-09 | GRAL | GRAIL, Inc. | S — Open-market sale | 123.5K | $49.92 | $6.16M |
| 2026-03-10 | GRAL | GRAIL, Inc. | S — Open-market sale | 258 | $46.73 | $12K |
| 2026-03-10 | GRAL | GRAIL, Inc. | S — Open-market sale | 7.2K | $47.93 | $345K |
| 2026-03-10 | GRAL | GRAIL, Inc. | S — Open-market sale | 980 | $53.01 | $52K |
| 2026-03-04 | GRAL | GRAIL, Inc. | S — Open-market sale | 1.7K | $51.84 | $89K |
| 2026-03-04 | GRAL | GRAIL, Inc. | S — Open-market sale | 35.8K | $50.09 | $1.79M |
| 2026-02-09 | TWST | Twist Bioscience Corp | A — Grant or award | 5.1K | $0.00 | |
| 2025-12-05 | GRAL | GRAIL, Inc. | S — Open-market sale | 1.6K | $97.28 | $156K |
| 2025-12-05 | GRAL | GRAIL, Inc. | S — Open-market sale | 8.2K | $96.22 | $792K |
| 2025-12-05 | GRAL | GRAIL, Inc. | S — Open-market sale | 15.4K | $95.28 | $1.46M |
| 2025-12-05 | GRAL | GRAIL, Inc. | S — Open-market sale | 14.8K | $94.43 | $1.40M |
| 2025-10-15 | GRAL | GRAIL, Inc. | S — Open-market sale | 7.2K | $68.88 | $499K |
| 2025-05-02 | GRAL | GRAIL, Inc. | S — Open-market sale | 94.0K | $33.93 | $3.19M |
| 2025-03-11 | GRAL | GRAIL, Inc. | S — Open-market sale | 7.6K | $31.21 | $238K |
| 2024-10-17 | GRAL | GRAIL, Inc. | S — Open-market sale | 123.5K | $14.02 | $1.73M |
| 2024-10-07 | GRAL | GRAIL, Inc. | A — Grant or award | 45.8K | $12.57 | $576K |
| 2024-10-07 | GRAL | GRAIL, Inc. | A — Grant or award | 214.2K | $12.57 | $2.69M |
Robert P. Ragusa is the Chief Executive Officer and Director of GRAIL, Inc., a healthcare company specializing in early cancer detection technologies. He has been involved in the company through various SEC filings, indicating his active role in corporate governance.…
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($17.92M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live RAGUSA ROBERT P profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.